PEP-1-GLRX1 protein exhibits anti-inflammatory effects by inhibiting the activation of MAPK and NF-κB pathways in Raw 264.7 cells

• Published in: BMB reports Vol. 53; no. 2; pp. 106 - 111
• Main Authors: Shin, Min Jea, Kim, Dae Won, Choi, Yeon Joo, Cha, Hyun Ju, Lee, Sung Ho, Lee, Sunghou, Park, Jinseu, Han, Kyu Hyung, Eum, Won Sik, Choi, Soo Young
• Format: Journal Article
• Language: Korean
• Published: 생화학분자생물학회 28-02-2020
• Subjects: Inflammation; MAPK; NF-kB; PEP-1-GLRX1; Protein therapy; Inflammation; PEP-1-GLRX1; MAPK; NF-{\kappa}B; Protein therapy
• ISSN: 1976-6696; 1976-670X

Glutaredoxin 1 (GLRX1) has been recognized as an important regulator of redox signaling. Although GLRX1 plays an essential role in cell survival as an antioxidant protein, the function of GLRX1 protein in inflammatory response is still under investigation. Therefore, we wanted to know whether transduced PEP-1-GLRX1 protein inhibits lipopolysaccharide (LPS)- and 12-O-tetradecanoyl phorbol-13-acetate (TPA)-induced inflammation. In LPS-exposed Raw 264.7 cells, PEP-1-GLRX1 inhibited cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), activation of mitogen activated protein kinases (MAPKs) and nuclear factor-kappaB (NF-κB) expression levels. In a TPA-induced mouse-ear edema model, topically applied PEP-1-GLRX1 transduced into ear tissues and significantly ameliorated ear edema. Our data reveal that PEP-1-GLRX1 attenuates inflammation in vitro and in vivo, suggesting that PEP-1-GLRX1 may be a potential therapeutic protein for inflammatory diseases. [BMB Reports 2020; 53(2): 106-111]